Spikevax XBB.1.5 0.1 mg/mL dispersion for injection

Spikevax XBB.1.5 50 micrograms dispersion for injection

Spikevax XBB.1.5 50 micrograms dispersion for injection in pre-filled syringe

Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 6 months of age and older.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.4-5 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax bivalent Original/Omicron BA.1 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax (Previously COVID-19 Vaccine Moderna)

Emergency Use Authorization has been granted in Qatar for Spikevax (COVID-19 Vaccine Moderna) to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Summary of Product Characteristics

Tools

Temperature Excursion Tool

See what to do with vials of the Moderna COVID-19 Vaccine that may have experienced a temperature excursion prior to administering.

Contact Moderna

00800101103

8am-5pm AST – Sun - Thr
EMEAMedinfo@modernatx.com